PT-141 (Bremelanotide) vs Melanotan-2: Full Comparison

Two peptides, one receptor family, and two completely different regulatory destinies. That’s the short version of the PT-141 and Melanotan-2 story — and it’s a far stranger tale than most side-by-side comparisons let on, starting with a University of Arizona lab that set out to build a better sunless tan and ended up, decades later, handing one of its molecules an FDA approval. Both compounds are sold by Crown Peptides as unapproved research chemicals, intended strictly for laboratory and in-vitro research use, not for human consumption.

• PT-141 (bremelanotide) and Melanotan-2 both descend from the same University of Arizona melanocortin research program and share a near-identical cyclic peptide backbone.
• Bremelanotide, the active molecule in PT-141, is the FDA-approved drug substance in Vyleesi — but only for a narrow, specific indication (HSDD in premenopausal women), and that approval belongs to the branded prescription drug, not to Crown Peptides’ research-grade PT-141 vials.
• Melanotan-2 has never been approved by the FDA or any other regulator anywhere, and multiple agencies have issued public warnings about unlicensed injectable Melanotan-2 products.
• Mechanistically, PT-141 leans toward MC4R activity while Melanotan-2 is a broader, non-selective agonist that also strongly engages MC1R — the receptor behind pigmentation.
• Named human research on both molecules goes back to the mid-1990s, including a documented phase-I pilot study on Melanotan-2 and a placebo-controlled crossover trial on its erectile effects.

Same Family Tree, Two Very Different Branches

If you laid the structures of these two peptides side by side, you’d have trouble spotting the difference at first glance. Both are cyclic heptapeptides built around the same core pharmacophore lifted from alpha-melanocyte-stimulating hormone (α-MSH), the body’s own signal for triggering melanin production. Swap out a single amide group at the C-terminus, and Melanotan-2 becomes bremelanotide — the active compound behind PT-141. That one atom-level difference is the entire hinge on which this comparison turns.

It’s not an exaggeration to say these two molecules are cousins in the truest sense — not just similar in concept, but literally derived from one another in a single research program. Both are cyclic heptapeptides, meaning the linear chain of amino acids is closed into a ring through a lactam bridge formed between the side chains of an aspartic acid and a lysine residue. That ring is what locks the peptide backbone into the rigid, receptor-favoring conformation that gives both molecules their outsized potency compared with linear α-MSH analogs — and the D-phenylalanine residue sitting in the middle of the ring is what makes both peptides far more resistant to enzymatic breakdown than the natural hormone, since most proteases aren’t built to cleave a D-amino acid bond.

That shared ancestry means a lot of what applies to one applies to the other structurally and mechanistically. But it also means the differences that do exist are worth taking seriously, because they’re the reason one molecule ended up as a prescription drug and the other became a global regulatory headache.

The Tan That Started a Drug

The story begins in the 1980s at the University of Arizona, where researcher Victor Hruby and colleagues were working on synthetic analogs of α-MSH — the peptide hormone that darkens skin by binding melanocortin receptors on melanocytes. The goal was straightforward on paper: build a more stable, more potent version of a natural hormone that could deliver a tan without UV exposure. What came out of that lab were two lead candidates, Melanotan-I (later developed separately into the drug afamelanotide) and Melanotan-2, a cyclic, superpotent peptide that outperformed the natural hormone by a wide margin in early testing.

The first documented human work on Melanotan-2 was a pilot phase-I clinical study run by researchers including Dorr and colleagues at the University of Arizona, published in Life Sciences in 1996. It was a small, deliberately cautious study — three healthy male volunteers received subcutaneous Melanotan-2 on an alternating schedule with placebo over two weeks, with the dose escalated in small increments from 0.01 mg/kg up toward 0.03 mg/kg. Even at those low, carefully escalated doses, two of the three subjects showed measurably increased pigmentation in the face, upper body, and buttock, confirmed both by quantitative reflectance measurement and simple visual inspection roughly a week after dosing ended. The researchers concluded that just five low-dose injections were enough to produce a visible tanning response and recommended 0.025 mg/kg/day as the target dose for future phase-I work — a real, citable piece of the compound’s research record, not internet folklore.^[1]

Here’s where the story takes its famous turn. According to the often-recounted history of the program, one of the Arizona researchers involved in the tanning work, Mac Hadley, self-administered a larger-than-intended dose of Melanotan-2 during early testing and reported an unmistakable, unplanned side effect: a spontaneous erection alongside the expected tanning response. Anecdote or not as the precise origin story, what’s beyond dispute is that Melanotan-2’s activity at melanocortin receptors beyond MC1R was real and reproducible enough that it redirected an entire branch of the research program toward sexual function. That pivot is what eventually produced bremelanotide. These informal reports are not research data, and Crown Peptides does not condone personal or human use of research compounds.

This connective thread — tanning peptide accidentally reveals sexual-function activity, which then gets isolated into a purpose-built molecule — is genuinely one of the more interesting discovery stories in peptide science. It also explains why anyone researching PT-141 today is, in a real sense, studying a direct descendant of the original Arizona tanning program.

From Shared Origin to Split Destiny

By 2000, Palatin Technologies — which had licensed the melanocortin peptide portfolio from the University of Arizona’s licensing arm, Competitive Technologies — made a pivotal call. It stopped development of Melanotan-2 itself and shifted its resources toward bremelanotide, the des-amide metabolite of Melanotan-2 that appeared to retain the sexual-function activity with a cleaner development profile. The relationship between Palatin and Competitive Technologies wasn’t entirely smooth; the two parties ended up in a legal dispute over rights to the melanocortin portfolio that wasn’t resolved until a 2008 settlement confirmed Palatin’s rights to bremelanotide going forward. That single corporate decision — walking away from Melanotan-2 and doubling down on its cleaner cousin — is arguably the moment these two molecules’ regulatory paths permanently diverged.

Bremelanotide went on to a formal, FDA-regulated clinical development program. Melanotan-2, meanwhile, never had a company steering it through that pipeline — and it leaked into the gray market as a research and body-modification compound anyway, sold online for tanning and libido purposes without ever going through a regulatory approval process.

That divergence is the single most important thing to understand about this pair, and it’s worth stating precisely: bremelanotide, the molecule, secured a real FDA approval. Melanotan-2 never has, anywhere. Those are two different outcomes for two structurally related but distinct compounds, and conflating them does a disservice to how genuinely interesting — and genuinely different — their stories are.

Vyleesi: A Real Approval, With a Narrow Lane

In June 2019, the FDA approved bremelanotide under the brand name Vyleesi as a subcutaneous injection for a specific indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, where the low desire causes marked distress and isn’t better explained by another medical condition, relationship issue, or medication.^[2] It was only the second drug ever approved in the US specifically for low sexual desire in women, and the first delivered by injection rather than a daily pill.

The approved product is dosed at 1.75 mg via a single-use autoinjector, taken as needed at least 45 minutes before anticipated sexual activity, with a hard ceiling of one dose per 24 hours and no more than eight doses a month. In the pivotal trials that supported approval, the most commonly reported effects were nausea, flushing, and injection-site reactions — findings that are part of the public prescribing record, not speculation.

The approval rested on two identical, appropriately sized Phase 3 trials — known together as the RECONNECT studies — that randomized 1,267 premenopausal women with HSDD to either bremelanotide 1.75 mg or placebo, taken as needed over 24 weeks, and were published in Obstetrics & Gynecology in 2019. Across both studies, women on bremelanotide showed statistically significant improvements in sexual desire scores and significant reductions in the distress associated with low desire, compared with placebo, with nausea, flushing, and headache as the most frequent adverse events, most of them mild to moderate.^[3] That’s a meaningfully larger and more rigorous evidence base than the pilot-scale work that first characterized Melanotan-2 in the 1990s — a direct reflection of how far the bremelanotide branch of this research program was carried once it had a dedicated development program behind it.

This is exactly the kind of nuance worth sitting with rather than glossing over. Vyleesi’s approval is a genuinely notable regulatory milestone for the melanocortin peptide class as a whole — proof that this receptor family can produce an approvable, clinically meaningful drug. But it’s an approval that belongs to a specific branded product, at a specific dose, in a specific delivery device, for a specific diagnosis. Crown Peptides’ PT-141 research product is the same underlying peptide — bremelanotide — supplied for laboratory and research applications; it is not Vyleesi, is not dispensed under a prescription, and isn’t a substitute for or equivalent to the approved drug. If you want the deeper dive into the compound’s dosing history, receptor pharmacology, and full FDA data trail, our PT-141 research guide lays it out in detail.

Melanotan-2: Popular, Persistent, and Still Unapproved

Melanotan-2 took the opposite road. No company ever filed for its approval anywhere in the world, and it has never cleared a formal regulatory review as a medicine in any jurisdiction. That hasn’t stopped it from becoming one of the most searched, most discussed, and most widely distributed compounds in the online peptide space — a genuinely popular subject of self-directed and informal research interest, built largely on its dual tanning and libido activity.

Regulators have taken notice of the gap between that popularity and its approval status. The UK’s Medicines and Healthcare products Regulatory Agency has publicly warned against unlicensed Melanotan injections, and in the US, the FDA has formally classified Melanotan-2 as an unapproved new drug that cannot legally be distributed for human use — a position the agency has defended in enforcement proceedings against sellers who continued domestic distribution after being warned.^[4] None of that changes the fact that Melanotan-2 remains one of the most interesting molecules in the melanocortin family from a research standpoint — a non-selective agonist whose broad receptor activity makes it a genuinely useful tool compound for studying pigmentation and appetite pathways side by side. It just means the compound’s story, so far, has played out entirely in the research and regulatory-warning space rather than the pharmacy. For a full walkthrough of its receptor pharmacology and research history, see our Melanotan-2 guide, and our Melanotan-1 vs Melanotan-2 comparison if you’re weighing it against its non-cyclic sibling.

How They Actually Work: MC1R, MC3R, MC4R, and the Receptor Map

To understand why one molecule tans skin and boosts libido while the other is mostly about desire, you have to look at the melanocortin receptor family itself. There are five known melanocortin receptors (MC1R through MC5R), each with a distinct tissue distribution and downstream effect. MC1R sits on melanocytes and drives pigmentation. MC3R and MC4R are concentrated in the hypothalamus and central nervous system, where they’re tied to energy balance, appetite, and — critically for this comparison — sexual arousal pathways that sit upstream of the genital vascular response.

Melanotan-2 is a textbook non-selective agonist. It binds and activates MC1R, MC3R, MC4R, and MC5R with meaningful potency across the board, which is exactly why it produces both a pigmentation response and a pro-sexual response in the same molecule — it simply isn’t picky about which melanocortin receptor it lands on. That non-selectivity is a double-edged sword scientifically: it makes Melanotan-2 a useful pan-melanocortin research tool for mapping how these receptors interact across systems, but it’s also the reason its effects are harder to isolate and its overall effect profile — including the skin-darkening and appetite-suppressing effects that come along for the ride — is broader than a receptor-selective compound would produce.

Bremelanotide was engineered with more receptor precision in mind. It retains meaningful MC1R and MC3R activity but is understood to act with particular relevance at MC4R, the receptor most strongly implicated in central sexual arousal circuits within the paraventricular nucleus of the hypothalamus. That relative shift toward MC4R engagement is a large part of why bremelanotide’s clinical development could focus tightly on a single, well-defined therapeutic story — sexual desire — rather than the more scattershot effect profile of its non-selective cousin. It’s a great example of how a small structural tweak at the peptide level can meaningfully reshape a receptor binding profile, even when the overall backbone stays almost identical.

Mechanically, both compounds work the same way once they’ve found their receptor: melanocortin receptors are G-protein-coupled receptors that signal primarily through the Gs pathway, activating adenylate cyclase and raising intracellular cyclic AMP. In melanocytes, that cAMP surge drives the transcription machinery that ramps up melanin synthesis — the biochemical basis of the tanning response. In the hypothalamic neurons carrying MC3R and MC4R, the same basic second-messenger cascade instead modulates neuronal excitability in circuits tied to appetite and sexual motivation. It’s a nice illustration of a broader principle in receptor pharmacology: the same intracellular signal, cyclic AMP, can produce wildly different physiological outcomes depending entirely on which cell type and which neural circuit is doing the responding.

What the Research Actually Shows

Beyond the 1996 Arizona pilot study, one of the more detailed early human datasets on Melanotan-2 comes from a double-blind, placebo-controlled crossover study published in the International Journal of Impotence Research, which tested the compound in men with erectile dysfunction. The results were striking for a pilot-scale study: the compound induced measurable penile rigidity in the large majority of participants without additional sexual stimulation, and subjects reported enhanced sexual desire significantly more often on active drug than on placebo. Nausea and yawning were the most frequently reported side effects.^[5] That trial is a genuinely important data point in melanocortin research — it’s one of the studies that first demonstrated, in controlled human conditions, that activating this receptor family could reliably influence both physiological arousal and subjective desire, independent of the peripheral vascular mechanism that drugs like PDE5 inhibitors rely on.

Bremelanotide’s own clinical program built directly on that mechanistic foundation, eventually running the larger, better-controlled trials that supported the Vyleesi approval — including studies specifically measuring changes in desire using validated clinical instruments in premenopausal women, rather than the smaller erectile-function-focused pilot work done decades earlier with Melanotan-2.

Alongside the formal research, there’s also a large body of anecdotal, self-reported experience circulating in online peptide communities about both compounds — reports of tanning results, appetite changes, and subjective libido effects. That community-level chatter is worth acknowledging because it’s part of why both molecules generate so much ongoing research interest, but it’s exactly that: anecdotal and self-reported, not controlled data, and it shouldn’t be read as equivalent to the peer-reviewed and FDA trial evidence described above.

Purity Isn’t Optional With Cyclic Peptides Like These

Both PT-141 and Melanotan-2 share a structural feature that makes purity verification especially important: they’re cyclic peptides, held in their active conformation by an internal lactam bridge between the aspartic acid and lysine side chains. That cyclization is what gives both molecules their receptor potency and their resistance to rapid degradation — but it also means the synthesis process has more places where things can go wrong. An incomplete cyclization, a truncated sequence, or a diastereomer with the wrong D-Phe orientation can all look deceptively similar to the correct product on a casual inspection, yet behave completely differently at the receptor level.

That’s exactly why Crown Peptides tests every batch of PT-141 and Melanotan-2 with HPLC purity analysis and confirms molecular identity by mass spectrometry before it’s released, with a batch-specific Certificate of Analysis available for every product we sell. For a cyclic heptapeptide in this molecular weight range, HPLC is the tool that actually catches the failure modes that matter — truncated sequences, incomplete cyclization, and related synthesis byproducts that can sit within a percent or two of the correct retention time if a lab isn’t running a properly validated gradient. Mass spectrometry backs that up from a different angle entirely, confirming you’re looking at a compound with the exact molecular weight it should have — roughly 1025 g/mol for bremelanotide, roughly 1024 g/mol for Melanotan-2 — rather than a byproduct that merely looks similar on a chromatogram.

We also provide clear storage and handling guidance with every order, because lyophilized cyclic peptides in this class are sensitive to moisture, temperature cycling, and repeated freeze-thaw once reconstituted. Left at room temperature or cycled repeatedly between fridge and bench, the lactam-bridged ring structure that gives these peptides their potency is also the structure most vulnerable to slow hydrolytic degradation — which is why unopened vials belong in a freezer well below zero, reconstituted material belongs refrigerated and used within a defined window, and every vial we ship is traceable back to a specific synthesis batch with its own COA, not a generic spec sheet shared across production runs. It’s a testing standard we hold across the whole catalog, but it matters in a very concrete, structural way for exactly this pair of molecules.

Where the Research Goes From Here

The melanocortin receptor family is far from a finished research story. Palatin Technologies, the same company behind bremelanotide, has continued exploring more selective next-generation melanocortin agonists — including a compound known as PL-6983, designed specifically to retain MC4R activity while producing significantly smaller blood-pressure increases than bremelanotide showed in animal models. That program remains in preclinical development rather than approved use, and the company has said its primary clinical focus stays on bremelanotide for the time being — but PL-6983’s existence is a clear signal that the field sees real headroom left in this receptor family beyond the two molecules covered here, and that receptor selectivity is likely to keep improving with each successive generation of melanocortin peptide.

More broadly, melanocortin receptor pharmacology continues to draw research interest well beyond sexual function. MC4R in particular sits at the center of a whole separate research thread around energy homeostasis and appetite regulation — a pathway that’s drawn intense interest across the broader peptide field in recent years — while MC1R remains central to pigmentation research and inflammatory-pathway work tied to skin biology. That overlap is exactly why tool compounds with different selectivity profiles, like non-selective Melanotan-2 alongside the more MC4R-leaning bremelanotide, remain genuinely valuable for researchers trying to isolate which receptor is doing what in a given experimental system — you need both a broad-spectrum probe and a more targeted one to really pull a multi-receptor pathway apart. That’s a research landscape that’s still actively expanding, not one that peaked with a single approval back in 2019.

Two Molecules, One Receptor Family, Worth Understanding Together

What makes this pairing so worth studying isn’t just the shared backbone — it’s what happened after these two molecules split off from the same Arizona research program. One became a narrowly approved prescription medicine with a defined clinical dataset behind it. The other became a widely used, structurally fascinating non-selective tool compound that never went through that process at all. Understanding both, side by side, tells you more about melanocortin receptor pharmacology than studying either one in isolation ever could.

If your research calls for either compound — or both, for comparative work across the receptor family — Crown Peptides stocks lab-verified PT-141 and Melanotan-2, each backed by a batch-specific Certificate of Analysis. Browse the full research peptide range at crownpeptides.co.uk to see how these two fit alongside the rest of the melanocortin and sexual-function research lineup.

Is PT-141 the same thing as Vyleesi?

They share the same active molecule, bremelanotide, but they are not the same product. Vyleesi is a specific branded, FDA-approved formulation — a fixed 1.75 mg dose in a dedicated autoinjector, dispensed by prescription for HSDD in premenopausal women. Crown Peptides’ PT-141 is the research-grade peptide itself, supplied for laboratory and research use, not as a prescription drug or a substitute for one.

Why does Melanotan-2 cause a tan but PT-141 doesn’t, if they’re so similar?

It comes down to receptor selectivity. Melanotan-2 is a strong, non-selective agonist that hits MC1R — the pigmentation receptor — hard, alongside MC3R and MC4R. Bremelanotide’s binding profile leans more toward MC3R/MC4R activity, which is why its clinical development centered on sexual desire rather than pigmentation, even though some MC1R activity is still present.

Has Melanotan-2 ever been tested in human clinical studies?

Yes, in a limited, academic way — a 1996 University of Arizona pilot phase-I study looked at its tanning effects in three volunteers, and a separate placebo-controlled crossover study assessed its erectile and desire effects in men with erectile dysfunction. Neither study was part of an FDA approval pathway, and development of Melanotan-2 itself was discontinued around 2000 in favor of bremelanotide, which is why no approval process ever followed.

What’s the molecular difference between PT-141 and Melanotan-2?

Bremelanotide (PT-141) is essentially Melanotan-2 minus its C-terminal amide group — a linear-acid ending instead of an amide. That single structural change shifts the molecular formula from C50H69N15O9 to C50H68N14O10 and is enough to alter the compound’s receptor selectivity and pharmacokinetic profile.